DOP048 Efficacy and safety of dose de-escalation from 50 mg to 25 mg QD of obefazimod maintenance treatment: Analysis of a subset of patients with moderately to severely active ulcerative colitis (UC) who have completed 2 years with 25mg QD
Silvio Danese(Università Cattolica del Sacro Cuore), Séverine Vermeire(KU Leuven), Britta Siegmund(Charité - Universitätsmedizin Berlin), Takashi Hisamatsu(Kyorin University), Laurent Peyrin‐Biroulet(Inserm), Herbert Tilg(Innsbruck Medical University), M Dubinsky, D Jacobstein(Abivax (France)), F Cataldi(Abivax (France)), Kevin Shan(Abivax (France)), P Ploncard(Abivax (France)), Christian G. Rabbat(Abivax (France)), B E Sands(Icahn School of Medicine at Mount Sinai), Parambir S. Dulai(University of California San Diego)
Cited by 0
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
|Hepatology|2017|1.9k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
|The Lancet|2015|776
Common variants in the NLRP3 region contribute to Crohn's disease susceptibility
|Nature Genetics|2008|523